SPRUCE BIOSCIENCES INC - TERMINATION OF ALL LICENSES AND RIGHTS GRANTED TO KAKEN; NO UNRECEIVED MILESTONE PAYMENTS OR ROYALTIES DUE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2026
0mins
Should l Buy SPRB?
Source: moomoo
Licenses and Rights: The article discusses the granting of licenses and rights by Cotokaken, emphasizing the importance of these in the context of scientific research and development.
Termination of Agreements: It highlights that certain agreements or licenses may be terminated, which could impact ongoing projects or collaborations.
Financial Implications: The piece notes that there are no earned milestone payments associated with the licenses, indicating a potential financial strain or lack of revenue generation.
Royalty Ties: It mentions the absence of royalty ties, suggesting that the agreements do not include provisions for ongoing financial returns based on sales or usage of the licensed products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SPRB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SPRB
Wall Street analysts forecast SPRB stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 69.110
Low
160.00
Averages
230.50
High
283.00
Current: 69.110
Low
160.00
Averages
230.50
High
283.00
About SPRB
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Precious Metals Stocks Surge, Led by Aura Minerals
- Precious Metals Surge: Precious metals stocks collectively rose by approximately 3.3%, indicating strong market confidence in the sector, likely reflecting investors' demand for safe-haven assets amid economic uncertainty.
- Aura Minerals Leads: Aura Minerals saw its stock price increase by about 6.8%, making it one of the top performers of the day, suggesting its competitive position in the precious metals market and positive investor sentiment.
- SSR Mining Follows Suit: SSR Mining's stock rose by approximately 6.6%, demonstrating the company's solid performance in the precious metals sector, which may attract more investor interest in its future growth potential.
- Biotech and Precious Metals Thrive: On Wednesday, both biotechnology and precious metals stocks showed strong performance, indicating investors' preference for diversified portfolios, potentially leading to increased capital inflows for related companies.
See More
SPRUCE BIOSCIENCES INC - TERMINATION OF ALL LICENSES AND RIGHTS GRANTED TO KAKEN; NO UNRECEIVED MILESTONE PAYMENTS OR ROYALTIES DUE
Licenses and Rights: The article discusses the granting of licenses and rights by Cotokaken, emphasizing the importance of these in the context of scientific research and development.
Termination of Agreements: It highlights that certain agreements or licenses may be terminated, which could impact ongoing projects or collaborations.
Financial Implications: The piece notes that there are no earned milestone payments associated with the licenses, indicating a potential financial strain or lack of revenue generation.
Royalty Ties: It mentions the absence of royalty ties, suggesting that the agreements do not include provisions for ongoing financial returns based on sales or usage of the licensed products.
See More
SPRUCE BIOSCIENCES INC ANNOUNCES TERMINATION AGREEMENT WITH KAKEN PHARMACEUTICAL ON MARCH 16 - SEC FILING
Termination Agreement: Spruce Biosciences has entered into a termination agreement with Kaken Pharmaceutical, signaling a significant change in their partnership.
Impact on Operations: This agreement may affect Spruce's ongoing projects and future collaborations in the pharmaceutical sector.
See More
Spruce Biosciences Reports Disappointing FY EPS and Cash Position
- Disappointing Earnings: Spruce Biosciences reported a FY GAAP EPS of -$50.83, missing expectations by $29.59, indicating significant financial challenges that may undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $48.9 million in cash and cash equivalents, excluding $15 million in gross proceeds from a loan facility with Avenue Capital, highlighting its reliance on external financing.
- Funding for Operations: The company expects its current cash reserves to fund its operating plan into early 2027, beyond the anticipated BLA submission for TA-ERT, providing some financial stability for future product development.
- Growth Capital Pursuit: Spruce Biosciences is seeking up to $50 million in growth capital, aimed at enhancing its financial flexibility and supporting future business expansion despite its current disappointing financial performance.
See More
Spruce Biosciences Advances TA-ERT for MPS IIIB Treatment
- Positive FDA Meetings: Spruce Biosciences successfully held two Type B meetings with the FDA, confirming that clinical data for TA-ERT could serve as a reasonable surrogate endpoint for accelerated approval, with a BLA submission anticipated in Q4 2026, potentially providing the first treatment option for MPS IIIB patients and significantly enhancing the company's market outlook.
- Executive Appointment: The company appointed Dale Hooks as Chief Commercial Officer, who brings over 30 years of marketing experience in the rare disease sector to drive the commercialization of TA-ERT, enhancing the company's competitive edge in the upcoming product launch and demonstrating strong confidence in future growth.
- Funding Support: Spruce Biosciences secured a loan facility with Avenue Capital for up to $50 million in growth capital, with an initial tranche of $15 million fully funded in January 2026, which will support the continued development and potential commercial launch of TA-ERT, ensuring the company's financial stability.
- Financial Performance: As of December 31, 2025, the company reported cash and cash equivalents of $48.9 million, expected to fund operations into early 2027, while R&D expenses decreased to $19.5 million compared to 2024, reflecting effective resource allocation and focus on core projects.
See More
Spruce Biosciences Delays FDA Submission Timeline
- Submission Delay: Spruce Biosciences announced a delay in its FDA submission for enzyme replacement therapy to Q4 2026, pushing back from the previously expected Q1 2026, which may impact its competitiveness in the rare disease market.
- FDA Meeting Progress: The company has held two meetings with the FDA, discussing clinical data and regulatory strategy in the first meeting, while the second focused on chemistry, manufacturing, and controls (CMC) requirements, indicating proactive engagement with regulators during the application process.
- Confidence in Clinical Data: Despite the delayed submission, CEO Javier Szwarcberg expressed confidence in the long-term data for TA-ERT, asserting that significant clinical benefits in cognition, communication, and motor skills could drive future market acceptance of the therapy.
- Market Sentiment Analysis: Although shares fell 8% due to the delay, retail sentiment around Spruce Biosciences stock remained in the 'bullish' territory on Stocktwits over the past 24 hours, reflecting investor confidence in the company's future potential.
See More
Precious Metals Stocks Surge, Led by Aura Minerals
- Precious Metals Surge: Precious metals stocks collectively rose by approximately 3.3%, indicating strong market confidence in the sector, likely reflecting investors' demand for safe-haven assets amid economic uncertainty.
- Aura Minerals Leads: Aura Minerals saw its stock price increase by about 6.8%, making it one of the top performers of the day, suggesting its competitive position in the precious metals market and positive investor sentiment.
- SSR Mining Follows Suit: SSR Mining's stock rose by approximately 6.6%, demonstrating the company's solid performance in the precious metals sector, which may attract more investor interest in its future growth potential.
- Biotech and Precious Metals Thrive: On Wednesday, both biotechnology and precious metals stocks showed strong performance, indicating investors' preference for diversified portfolios, potentially leading to increased capital inflows for related companies.
See More
SPRUCE BIOSCIENCES INC - TERMINATION OF ALL LICENSES AND RIGHTS GRANTED TO KAKEN; NO UNRECEIVED MILESTONE PAYMENTS OR ROYALTIES DUE
Licenses and Rights: The article discusses the granting of licenses and rights by Cotokaken, emphasizing the importance of these in the context of scientific research and development.
Termination of Agreements: It highlights that certain agreements or licenses may be terminated, which could impact ongoing projects or collaborations.
Financial Implications: The piece notes that there are no earned milestone payments associated with the licenses, indicating a potential financial strain or lack of revenue generation.
Royalty Ties: It mentions the absence of royalty ties, suggesting that the agreements do not include provisions for ongoing financial returns based on sales or usage of the licensed products.
See More
SPRUCE BIOSCIENCES INC ANNOUNCES TERMINATION AGREEMENT WITH KAKEN PHARMACEUTICAL ON MARCH 16 - SEC FILING
Termination Agreement: Spruce Biosciences has entered into a termination agreement with Kaken Pharmaceutical, signaling a significant change in their partnership.
Impact on Operations: This agreement may affect Spruce's ongoing projects and future collaborations in the pharmaceutical sector.
See More
Spruce Biosciences Reports Disappointing FY EPS and Cash Position
- Disappointing Earnings: Spruce Biosciences reported a FY GAAP EPS of -$50.83, missing expectations by $29.59, indicating significant financial challenges that may undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $48.9 million in cash and cash equivalents, excluding $15 million in gross proceeds from a loan facility with Avenue Capital, highlighting its reliance on external financing.
- Funding for Operations: The company expects its current cash reserves to fund its operating plan into early 2027, beyond the anticipated BLA submission for TA-ERT, providing some financial stability for future product development.
- Growth Capital Pursuit: Spruce Biosciences is seeking up to $50 million in growth capital, aimed at enhancing its financial flexibility and supporting future business expansion despite its current disappointing financial performance.
See More
Spruce Biosciences Advances TA-ERT for MPS IIIB Treatment
- Positive FDA Meetings: Spruce Biosciences successfully held two Type B meetings with the FDA, confirming that clinical data for TA-ERT could serve as a reasonable surrogate endpoint for accelerated approval, with a BLA submission anticipated in Q4 2026, potentially providing the first treatment option for MPS IIIB patients and significantly enhancing the company's market outlook.
- Executive Appointment: The company appointed Dale Hooks as Chief Commercial Officer, who brings over 30 years of marketing experience in the rare disease sector to drive the commercialization of TA-ERT, enhancing the company's competitive edge in the upcoming product launch and demonstrating strong confidence in future growth.
- Funding Support: Spruce Biosciences secured a loan facility with Avenue Capital for up to $50 million in growth capital, with an initial tranche of $15 million fully funded in January 2026, which will support the continued development and potential commercial launch of TA-ERT, ensuring the company's financial stability.
- Financial Performance: As of December 31, 2025, the company reported cash and cash equivalents of $48.9 million, expected to fund operations into early 2027, while R&D expenses decreased to $19.5 million compared to 2024, reflecting effective resource allocation and focus on core projects.
See More
Spruce Biosciences Delays FDA Submission Timeline
- Submission Delay: Spruce Biosciences announced a delay in its FDA submission for enzyme replacement therapy to Q4 2026, pushing back from the previously expected Q1 2026, which may impact its competitiveness in the rare disease market.
- FDA Meeting Progress: The company has held two meetings with the FDA, discussing clinical data and regulatory strategy in the first meeting, while the second focused on chemistry, manufacturing, and controls (CMC) requirements, indicating proactive engagement with regulators during the application process.
- Confidence in Clinical Data: Despite the delayed submission, CEO Javier Szwarcberg expressed confidence in the long-term data for TA-ERT, asserting that significant clinical benefits in cognition, communication, and motor skills could drive future market acceptance of the therapy.
- Market Sentiment Analysis: Although shares fell 8% due to the delay, retail sentiment around Spruce Biosciences stock remained in the 'bullish' territory on Stocktwits over the past 24 hours, reflecting investor confidence in the company's future potential.
See More
